Lab Institute 2013 is pleased to welcome these distinguished speakers. These individuals have demonstrated excellence in the industry and we thank them for sharing their knowledge with the Lab Institute community.
Stewart S. Adelman, M.T. (ASCP),
CEO, Puget Sound Institute of Pathology
Stewart S. Adelman joined Puget Sound Institute of Pathology (PSIP) in July 2011 as their Chief Executive Officer. PSIP pathologists serve as medical directors of nine hospitals and are unique in that along with 15 board certified AP/CP staff pathologists, PSIP also has board certified clinical pathologists in the areas of transfusion medicine and microbiology. PSIP is the second largest pathology practice in the Puget Sound region in the state of Washington. Mr. Adelman’s experience and leadership in strategic planning and technology development will be keys to the practice navigating the shifting healthcare environment.
Before joining PSIP, Mr. Adelman served as Chief Operating Officer/General Manager of PACLAB Network Laboratories, a regional laboratory organization with 15 hospital-based laboratories, also located in the Puget Sound region. In this role, Mr. Adelman provided organizational leadership in the development of standardizing the PACLAB service product. The unique business model created required a unique set of skills to motivate and direct certain functional groups across the laboratory network including: technical operations, financial performance, marketing, logistics, information systems, and client services. Working directly with Member hospital executives and laboratory operations managers, he was able to ensure the growth and continued success of the organization. During Mr. Adelman’s fourteen year leadership role at PACLAB revenues grew from $10 million (1997) to nearly $100 million (2011).
Mr. Adelman has significant clinical laboratory experience. Prior to joining PACLAB, Mr. Adelman served as the Laboratory Director at Children’s Hospital and Regional Medical Center in Seattle. Previously he held hospital supervisory positions in Chemistry, Hematology, and Blood Bank.
Mr. Adelman received a Bachelor of Science, Microbiology from Florida Atlantic University at Boca Raton, and holds a M.T. (A.S.C.P.) licensure.
Edward Ashwood M.D.,
President and CEO, ARUP Laboratories
Dr. Ashwood is the president and chief executive officer at ARUP and a professor of pathology at the University of Utah School of Medicine. Dr. Ashwood joined ARUP in 1985. He received his M.D. from the University of Colorado and completed a laboratory medicine residency in clinical pathology at the University of Washington. He is board certified in clinical and chemical pathology, and his research interests include the clinical chemistry of pregnancy. He is the co-editor of the Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, Tietz Fundamentals of Clinical Chemistry, and Fundamentals of Molecular Diagnostics.
Chief of USA Business Development, BITAC MAP SL
Ginger Baker is a consultant in LEAN six-sigma laboratory operations, clinical informatics, and point-of-care testing products and models, writer for Advance Magazine and Acute Care, contributor to CLSI, Laboratory Operations Manager at St Peter’s Hospital in Helena, Mont., and the Chief of USA Business Development for BITAC MAP. She has been facilitating early adoption of clinical informatics her entire career and with the advent of HITECH, partnered with BITAC to bring a European resource to the new USA marketplace.
Michael S. Barr, M.D., MBA, FACP,
Senior Vice President, Division of Medical Practice, Professionalism & Quality (MPPQ), American College of Physicians
Michael S. Barr is Senior Vice President, Division of Medical Practice, Professionalism & Quality (MPPQ) for the American College of Physicians and a board-certified internist. The MPPQ division is responsible for promoting patient-centered care and professionalism through the development of innovative products and services, quality improvement programs, and educational initiatives for internists and other healthcare professionals. The division includes the Center for Practice Improvement & Innovation, the Center for Quality, Office of Grants, the Center for Ethics & Professionalism, and the Medical Laboratory Evaluation Program. Dr. Barr's portfolio also includes policy development and advocacy for issues including the patient-centered medical home, inter-professional team-based care, and health information technology.
Prior to joining the ACP staff in February 2005 as Vice President, Practice Advocacy & Improvement, Dr. Barr served as the Chief Medical Officer for Baltimore Medical System, Inc., a Joint Commission accredited, multi-site federally qualified community health center from 1999 to 2005. Dr. Barr was on the faculty of the Division of General Internal Medicine at Vanderbilt University from 1993 to 1998 and held various administrative positions including Physician Director, Medical Management Programs for the Vanderbilt Medical Group. Dr. Barr also served in the United States Air Force from 1989 to 1993.
Dr. Barr attended New York University School of Medicine (1986) and completed his residency in Internal Medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago, Illinois (1989). He received a Masters of Business Administration from Vanderbilt Owen Graduate School of Management (1996), and a Bachelor of Science degree in Forest Biology from the State University of New York, College of Environmental Science and Forestry (1982).
Dr. Barr holds part-time faculty appointments at Johns Hopkins University and The George Washington University. He currently serves on the Boards of Trustees for Baltimore Medical System, Inc. (a federally qualified community health center), IHE-USA, and the National eHealth Collaborative (NeHC). He is also a member of the Health Information Technology Policy Committee Meaningful Use Workgroup.
Jeffrey C. Bauer, Ph.D.,
Independent Health Futurist and Medical Economist
Dr. Bauer is an internationally recognized health futurist and medical economist. As an independent industry thought leader, he forecasts the evolution of health care and develops practical approaches to improving the medical sector of the American economy. He is widely known for his specific proposals to create an efficient and effective health care delivery system through multi-stakeholder partnerships and other initiatives focused in the private sector.
Dr. Bauer has published more than 225 articles, books, Web pages, and videos on health care delivery. He speaks frequently to national and international audiences about key trends in health care, medical science, technology, information systems, reimbursement, public policy, health reform, and creative problem-solving. Dr. Bauer is quoted often in the national press and writes regularly for professional journals that cover the business of health care.
His latest books are Paradox and Imperatives in Health Care: How Efficiency, Effectiveness, and E-Transformation Can Conquer Waste and Optimize Quality (Productivity Press, 2008) and Statistical Analysis for Health Care Decision-Makers (CRC Press, 2009). His two previous books are Telemedicine and the Reinvention of Health Care: The Seventh Revolution in Medicine (McGraw-Hill, 1999) and Not What the Doctor Ordered (McGraw-Hill, 1998). He is currently finishing a book on strategic forecasting methodologies, Upgrading the Crystal Ball for Business Insight: Five Reasons Why Forecasting Must Replace Predicting and How to Make the Strategic Change (Taylor & Francis, Spring 2013).
As a consultant, he has assisted hundreds of provider, purchaser, and payer organizations with strategic planning and performance improvement. He served as Vice President for Health Care Forecasting and Strategy for ACS, a Xerox Company, from 1999 to 2010. His previous consulting firm, The Bauer Group, specialized in consumer-focused strategic planning and development of clinical affiliation agreements for multi-hospital networks from 1984 to 1992.
He received his Ph.D. in economics from the University of Colorado-Boulder. He graduated from Colorado College in Colorado Springs with a B.A. in economics and completed a certificate in political studies at the University of Paris (France). During his academic career, he was a Boettcher Scholar, a Ford Foundation Independent Scholar, a Fulbright Scholar (Switzerland), and a Kellogg Foundation National Fellow. Dr. Bauer lives in Chicago, where he occasionally displays his paintings in art galleries. He is an avid fan of music and member of the Governing Board of the Chicago Symphony Association.
George B. Breen,
Member of the Firm, Epstein Becker & Green, P.C.
George B. Breen is a Member of the Firm in the Health Care and Life Sciences and Litigation practices. He is Chair of the firm's National Health Care and Life Sciences Practice Steering Committee.
- Defends clients undergoing investigation for health care fraud by the Department of Justice, the Department of Health and Human Services Office of the Inspector General, and other state and federal governmental authorities
- Serves as defense counsel in connection with False Claims Act cases (including qui tam litigation)
- Conducts compliance investigations and advises clients on compliance, reimbursement, and health regulatory issues
- Represents MCOs, HMOs, nursing homes, home health agencies, health care providers, manufacturers and suppliers before courts and administrative tribunals at the federal and state level, including challenges to regulatory actions and disputes under government contracts
- Defends individuals and organizations against claims of malpractice, professional liability, and other litigation matters
- Advises clients on, and litigates, employment, labor, disability, non-compete and confidentiality matters
In addition to representing clients, Mr. Breen serves as a mediator and arbitrator for the American Health Lawyers Association's Dispute Resolution Service.
A litigator for more than 20 years, Mr. Breen co-chairs the Health Care and Life Sciences Litigation and Government Investigations practice group at Epstein Becker Green. He also serves as Vice Chair of the American Health Lawyers Association's Health Care Liability and Litigation Practice Group.
Mr. Breen has been a member of a variety of professional organizations and is a Past President and member of the Board of Directors of the District of Columbia Defense Lawyers Association. He is also a frequent lecturer and author on issues related to health care fraud and abuse, corporate compliance, and trial practice.
Mr. Breen has earned an "AV Preeminent" Peer Review Rating by Martindale-Hubbell, signifying the highest level of professional excellence. In 2010, he was named an "Outstanding Healthcare Litigator" by Nightingale's Healthcare News, one of only 10 lawyers across the country selected for this honor. In 2012 and 2013, he was selected for inclusion in Washington, DC Super Lawyers.
In addition to his professional activities, Mr. Breen devotes significant time to charitable and nonprofit organizations. He also leads Epstein Becker Green's Pro Bono Committee in the firm's Washington, DC, office.
Chief Executive Officer, Manhattan Labs
Ken brings more than 20 years of lab industry experience to Manhattan Labs. Most recently, Ken served as President of Strand Diagnostics, LLC. where he was responsible for launching the know error® system and developed the company into a profitable, high-growth enterprise. He has extensive experience developing strategic partnerships with key decision makers in the industry, including physicians, managed care payers, hospitals and reference laboratories.
Before Strand Diagnostics, Ken held executive leadership positions in sales and marketing at LabCorp, Quest Diagnostics and McKesson. He currently serves as an advisory board member to several healthcare industry companies. Ken believes strongly in the Manhattan Labs brand and our bright future as the premier service oriented, high quality independent clinical lab in the New York City metropolitan area.
James C. Clark, B.S., S.M. (ASCP),
Microbiology Department Manager, Professional Clinical Laboratories (PCL) Alverno
Jim Clark is the microbiology department manager of for PCL Alverno Laboratory. PCL Alverno is the freestanding central laboratory for the integration of two health systems (Franciscan Alliance and Presence Health ) comprised of 26 acute-care hospitals and associated physicians and clinics located in Indiana and Illinois. The central laboratory microbiology department provides comprehensive microbiology services in the areas of bacteriology, mycology, parasitology, and mycobacteriology and processes approximately 700,000 tests annually.
Clark joined the laboratory as microbiology department supervisor three months after it opened. At that time the department had a staff of thirteen and serviced six hospitals. In 2005 and 2008, expansions occurred that added 20 hospitals. Clark was a part of the integration team responsible for determining transition processes and testing of computer interfaces to assure that quality and service levels were maintained at the highest possible level. In 2008 Clark accepted the department manager position and currently oversees the operation of the department with 64 FTEs and is an active participant in the infection prevention committee of each of the facilities. In 2010 he co-authored an article published in the Journal of Clinical Microbiology, Direct Ertapenem Disk Screening Method for Identification of KPC-Producing Klebsiella pneumoniae and Escherichia coli in Surveillance Swab Specimens. In 2013, Siemens Healthcare Diagnostics named Alverno as its Microbiology Innovation Center for the United States. Alverno is currently working with Siemens, Bruker, and Copan to implement full microbiology automation. Clark has 37 years of supervisory experience in microbiology that includes previous positions in a small core laboratory and three acute care facilities.
Richard Cooper, Esq.,
Member, McDonald Hopkins LLC
Rick is the Manager of the firm’s National Healthcare Practice Group and is co-chair of its Healthcare Restructuring Practice Group. He also serves on the firm's Board of Directors. He focuses his national practice in healthcare law, representing clients in transactional, restructuring, corporate, regulatory, reimbursement, contractual, strategic planning, and venture matters. Practice group clients include private practice and academic physician groups, hospitals and health systems (including physician-owned hospitals), physician networks, laboratories, healthcare associations and societies, multi-specialty clinics, medical staffs, outpatient medical facilities, home health providers, mental health/substance abuse facilities, occupational medicine companies, healthcare technology companies, and healthcare billing and management companies.
Rick has a national practice in the representation of laboratories and pathology groups. McDonald Hopkins represents in excess of 400 pathology groups and a substantial number of laboratories. Rick is a frequent speaker on laboratory and pathology issues at state and national conferences and is a frequent contributor to laboratory and pathology publications.
Domnita Crisan, M.D., Ph.D.,
Medical Director, Molecular Pathology, William Beaumont Hospital
Domnita Crisan has been Medical Director of the Molecular Pathology Laboratory at William Beaumont Hospital since 1990. She has been involved in molecular diagnostics for 23 years and has authored over 95 articles, invited papers, and editorials, 5 book chapters, and edited several books, including the recent Hematopathology: Genetic Mechanisms of Neoplastic Diseases.
Dr. Crisan has been a hematopathologist for 25 years. She has been active in the Association for Molecular Pathology since its inception, serving as elected officer in the organization's Training and Education, Nominating, and Clinical Practice Committees. Dr. Crisan has also been elected chair of the Molecular Pathology Division of AACC and served on the CME Committee of AACC. Since 2003, she has been a member of the editorial board of Molecular Diagnosis.
At Beaumont, Dr. Crisan is actively involved with the training of residents, fellows, and medical technologists in molecular diagnostics. Her research activity is focused on molecular abnormalities in leukemias and lymphomas and on genetic risk factors in cardiovascular disease.
Chairman and CEO, MEDgle
Ash Damle is a global entrepreneur and technologist who is deeply rooted in the application of big data to health, energy, and retail, and its intersection with design. He graduated from the Massachusetts Institute of Technology (MIT) in both Computer Science and Mathematics and has received patents in real-time unstructured semantic analytics.
Throughout his career, Ash has looked for opportunities to apply big data and big analytics/practical artificial intelligence. He has worked with the MIT Media Lab, MIT, U.S. Navy, California Department of Corrections and Rehabilitation, law enforcement agencies, power production and distribution companies, and retailers such as J. Crew and Oakley in developing web-scale big data and big analytics solutions.
Ash's major passion is health. He is a leading innovator in big data and health looking to address health globally. Ash started MEDgle in 2006 focused on enabling scalable healthcare to address the increasing supply/demand imbalances of health worldwide. This is highlighted by the emerging global crisis with supply ratios as low as 6 physicians per 10,000 people and 14 per 10,000 in India and China respectively. MEDgle's mission is making elegant sense of the world’s health data to guide and scale care delivery.
Since MEDgle's start, it has served over 7.5 million visitors worldwide and has helped many people on their journey for health. Sitting at the juncture of big data, big analytics, health, and the cloud, MEDgle delivers simplified health to patients, providers, and payers through applications and APIs that enable reliable, scalable, and distributed care.
President and CEO, Sonora Quest Laboratories, LLC
David A. Dexter is the Managing Director for the Quest Diagnostics Operations in Arizona, serving as President and CEO for Sonora Quest Laboratories, LLC a joint venture between Quest Diagnostics and Banner Health (the largest non-secular health delivery system in the U.S.) and as President and CEO for Laboratory Sciences of Arizona, LLC which manages the 13 hospital laboratories for Banner Health in Arizona. The Phoenix Business Journal selected him as one of the Top 25 Most Admired CEOs in the Valley for 2009.
A Certified Six Sigma Green Belt, Mr. Dexter serves on the Board and as Board Chair for Arizona Health-e-Connectivity, the Board and Executive Committee of the Health Information Network of Arizona, the National Leadership Council for eHealth Initiative and their National Council for Diabetes and Technology, the Board of Chancellors for JDRF, the Leadership Council for the Arizona Diabetes Coalition, and the Board of Directors for the Arizona Chamber of Commerce and Industry. David is also a member of American Cancer Society’s CEOs Against Cancer.
Peter E. Fisher, M.D., MBA,
President and CEO of Health Network Laboratories; Clinical Laboratory Director
Dr. Peter Fisher is President and Chief Executive Officer of Health Network Laboratories, a multi-regional clinical laboratory with almost 1000 employees serving the needs of hospitals, physicians and patients in Pennsylvania and New Jersey.
During his tenure as President & CEO, and in his prior role as Chair of Department of Pathology & Laboratory Medicine, Dr. Fisher has introduced a broad range of initiatives aimed at optimizing patient-centered quality, efficiency, access and value in lab diagnostics. These include evidenced-based test utilization accompanied by algorithmic diagnostics and workflow, coupled with a culture committed to lean process flow and continuous improvement throughout the laboratory environment.
Dr. Fisher is a graduate of the Middlesex Hospital Medical School, University of London. He completed his pathology residency and a postgraduate Fellowship in Advanced Pathology at the College of Physicians & Surgeons of Columbia University, New York. Dr. Fisher is a Diplomate of the American Board of Pathology and received his MBA from the Columbia Business School. Dr. Fisher’s clinical expertise includes cardiovascular, pulmonary, genitourinary, gastrointestinal and autopsy pathology. Dr. Fisher’s research focuses on cancer biology, cardiovascular disease and development, and he has authored more than 60 original research articles.
Daniel E. Gospin,
Member of the Firm, Epstein Becker & Green, P.C.
Daniel E. Gospin is a Member of the Firm in the Health Care and Life Sciences practice of Epstein Becker Green, in the firm's Houston office. He represents a variety of health and life science entities, including hospitals, physician groups, pharmaceutical and medical device manufacturers, retail and specialty pharmacies, home health and hospice providers, dialysis companies, long term acute care facilities, nursing homes, durable medical equipment suppliers, and ambulatory surgery centers. Mr. Gospin also advises investors and other financial institutions that invest in or support the health care industry.
- Performs compliance effectiveness evaluations for health care entities and advises health care entities and Boards of Directors on the development and implementation of all aspects of a Corporate Compliance Program, including drafting policies and procedures, training modules and auditing/monitoring tools
- Advises investors and other financial institutions in the planning and structuring of health care transactions and business arrangements by conducting due diligence, completing regulatory filings and reviewing, drafting and negotiating agreements
- Counsels clients in the areas of federal and state fraud issues, including anti-kickback, self-referral and false claims
- Represents clients in all aspects of third party payor audits, including those conducted by Recovery Audit Contractors (RACs), Zone Program Integrity Contractors (ZPICs), and Medicare Administrative Contractors (MACs)
- Counsels health care and life science entities in connection with government investigations, including the negotiation of civil settlements and corporate integrity agreements
- Advises Boards of Directors of for-profit companies regarding compliance and fraud and abuse issues
- Advises clients on regulatory and reimbursement matters arising under Medicare, Medicaid and other third-party payment programs
- Advises on physician contracting arrangements and health care joint ventures
- Represents clients in pro bono matters including a national non-profit health care organization
Mr. Gospin frequently writes and speaks on matters concerning health care fraud and abuse and compliance. He is a co-author of a chapter in the Corporate Compliance Practice Guide: The Next Generation of Compliance, entitled "Specific Corporate Compliance Challenges by Industry: Healthcare."
While attending Brooklyn Law School, Mr. Gospin was an intern for the New York City Health and Hospitals Corporation.
Hakon Hakonarson, M.D., Ph.D.,
Director, Center for Applied Genomics, The Children’s Hospital of Pennsylvania and Associate Professor of Pediatrics, University Pennsylvania School of Medicine
Hakon Hakonarson is an Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine. A physician-scientist, he is the Director of The Children’s Hospital of Philadelphia’s Center for Applied Genomics (CAG), a high-throughput highly automated genotyping facility founded to identify the genetic causes of complex medical disorders in children, such as autism and cancer, with the objective of developing new therapies. The Center represents a $40 million commitment from CHOP to genotype approximately 100,000 children, a research undertaking that has gained nationwide attention, including news features in the Wall Street Journal, The New York Times, Time, Nature, and Science.
Dr. Hakonarson has an extensive track record in human genetics and has developed an international reputation amongst his peers. He has served previously in several senior posts in the biopharmaceutical industry, including as the Director of Inflammatory and Pharmacogenomics Research and the Vice President of Clinical Sciences and Development and CSO. Dr. Hakonarson has also been the Principal and Co-Principal Investigator on several NIH-sponsored grants, and he has published numerous high-impact papers on genomic discoveries and their translations in some of the most prestigious scientific medical journals, including Nature, Nature Genetics, and the New England Journal of Medicine. Time listed Dr. Hakonarson’s autism gene discovery (reported in Nature in 2009) among the top 10 medical breakthroughs of that year. With over ten years of experience in pioneering genomics research and genome-wide mapping and association studies, Dr. Hakonarson has intimate knowledge of the complexities of large-scale genomics projects and has put together the necessary infrastructure and workflow processes to unravel these complexities.
Eleanor Herriman, M.D., M.B.A.,
Managing Director, Advisory Services, G2 Intelligence
L. Eleanor J. Herriman, M.D., M.B.A. is a pathologist executive with 15+ years experience in the medical technology industry. She has worked across sectors with both small ventures and corporations. Her market experience spans the clinical laboratory, in vitro diagnostics, e-health, biotech, and strategy consulting for Bain & Company. Other key accomplishments include growing a venture with a CLIA lab and FDA PMA approved computer-assisted cytology instrument from start-up to publicly traded company (IPO raised $100 million).
She is the leader of G2 Intelligence’s advisory services, which provides strategic consulting and custom market research and assessments for a range of clients, including pathology groups, clinical labs, health systems, hospitals, medical centers, diagnostic technology companies, and investors.
She is the author of three G2 reports: Health Care Market Reforms: Implications and Prescriptions for Laboratories; How to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations; and Creating a Value-Driven Laboratory: Opportunities in the New Marketplace.
She earned her M.D. at Baylor College of Medicine, completed pathology residency at University of California San Francisco, and received an M.B.A. from Harvard Business School with highest honors (Baker Scholar).
President and Chief Operating Officer, Ober|Kaler
S. Craig Holden is President and Chief Operating Officer of Ober|Kaler. Over
the course of his distinguished career, he has represented clients in all
areas of the health care industry, with particular emphasis on advising
clients on Medicare and Medicaid fraud and abuse issues, pharmaceutical
pricing issues, Medicare and other third-party reimbursement issues and
general compliance matters. He has also represented numerous health care
industry clients in government fraud and abuse investigations.
Craig is a former trial attorney with the Inspector General Division, Office
of the General Counsel, Department of Health and Human Services. At HHS, he
was responsible for litigating actions imposing civil money penalties and
assessments, as well as suspensions from Medicare and Medicaid participation,
based on violations of the Medicare and Medicaid fraud and abuse statutes. He
has been extensively involved in issues arising under the anti-kickback
provisions of the Social Security Act and in the drafting and passage of the
Medicare and Medicaid Patient and Program Protection Action of 1987.
A frequent lecturer and author on Medicare and Medicaid fraud, abuse and
reimbursement issues, Craig is also is active in health care sections of the
American Bar Association and the District of Columbia Bar Association. He
serves on the advisory board of Washington G-2 Reports, an independent news
and information service covering the health care industry.
- American Bar Association
- American Health Lawyers Association
- District of Columbia Bar Association
- Ober|Kaler Board of Directors
- Washington G-2 Reports
- Listed in Expert Guides to the Leading Lawyers – Best of the Best USA
2007, Healthcare Category
- Listed in Maryland Super Lawyers, Health Care Law, 2007-2010
Listed since 2007 in The Best Lawyers in America, Health Law Category
Managing Partner, England & Company
Tim Johnson has over 15 years of financial advisory and investment banking experience focusing primarily on assisting clients achieve strategic objectives through mergers and acquisitions. He has advised clients and managed transactions in a wide range of industries including healthcare, financial services, information technology, distribution, security, telecommunications, media, and manufacturing.
Prior to joining England & Company, Mr. Johnson worked in Salomon Smith Barney's Global Mergers and Acquisitions Group and CIBC World Markets, advising clients on M&A transactions in a multitude of industries. Previously, he worked in the Financial Institutions Group at Friedman, Billings, Ramsey & Co., Inc. Mr. Johnson began his career at Arthur Andersen LLP, working in the Financial Services Division of the Audit and Advisory Group where he provided accounting and consulting services to clients in a number of industries.
Mr. Johnson, a Certified Public Accountant, earned his BS in Accounting, magna cum laude, and his MBA in Finance from the University of Maryland. He also has been a Guest Finance Lecturer at the Robert H. Smith Graduate School of Business, University of Maryland.
Dale R. Kahn, M.T. (ASCP),
Central Laboratory Director, PCL Alverno
Dale R. Kahn was part of the planning and design team that built Alverno Clinical Laboratory which first opened in 1999. Kahn accepted the role as Central Laboratory Director for Alverno in 2002. At that time, the laboratory consisted of a central laboratory facility in Northwest Indiana and six hospital laboratories from the Franciscan Alliance healthcare system. In 2005 Alverno expanded to service 18 hospitals by integrating with the Provena Health laboratories and to service all of the Franciscan Alliance hospital laboratories. In 2008 Alverno expanded to service 26 hospitals by integrating with the Resurrection Healthcare laboratories located in the Chicago market. Provena and Resurrection merged in 2012 to form Presence Health. Alverno currently manages the central laboratory facility along with 26 hospital laboratories in Indiana and Illinois for the Franciscan Alliance and Presence Health systems. Kahn directed this large and continuous expansion of the Alverno central laboratory facility through flexible design, focus on process and has developed many computerized solutions. In 2013, Siemens Healthcare Diagnostics named Alverno as its Microbiology Innovation Center for the United States. Alverno is currently working with Siemens, along with Copan and Bruker, to implement full microbiology automation. Alverno has also partnered with Purdue University Calumet through its CIVS (Center for Innovation through Visualization and Simulation) group to use 3D interactive modeling for the design of the automated microbiology laboratory. Kahn received a Bachelor of Science degree from Manchester College and has over 35 years of laboratory experience.
David P. King,
Chairman and Chief Executive Officer, Laboratory Corporation of America® Holdings and Chairman, American Clinical Laboratory Association
David P. King is Chairman and Chief Executive Officer of Laboratory Corporation of America® Holdings (LabCorp). LabCorp, one of the world’s largest clinical laboratories, has revenues of approximately $4.7 billion (2009) and more than 28,000 employees nationwide.
Prior to becoming Chief Executive Officer on January 1, 2007, Mr. King served as LabCorp’s Executive Vice President and Chief Operating Officer since 2005. Previously, he served as head of the Company’s US LABS / Esoterix Division, one of the nation’s leading specialty testing and cancer diagnostic laboratories, as well as Executive Vice President of Strategic Planning and Corporate Development. He is a member of the Company’s Management Committee.
Mr. King initially joined LabCorp as Senior Vice President, General Counsel and Chief Compliance Officer in 2001 after working for many years with the Company as an outside counsel. Prior to joining the Company, he was a partner with Hogan & Hartson L.L.P. in Baltimore, Maryland from 1992 to 2001. Mr. King is also on the board of The Personalized Medicine Coalition (PMC) which seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients.
Mr. King, 53, holds an AB degree, cum laude, from Princeton University and a JD degree, cum laude, from the University of Pennsylvania Law School.
Steven C. LaTourette,
President, McDonald Hopkins Government Strategies™, U.S. Representative (R-OH), 1995-2012
Steve, who served 18 years as a member of the U.S. House of Representatives from Northeast Ohio, is President of McDonald Hopkins Government Strategies™, a Washington-based subsidiary of McDonald Hopkins LLC that provides strategic counsel at the federal government level. A fiscally conservative, moderate Republican who strove to take a bipartisan and regional approach to governing, he is widely credited with leading the successful effort to save more than 1,100 jobs at Cleveland’s Defense Finance and Accounting Service and in assisting auto dealers impacted by the bankruptcy and bailout of GM and Chrysler.
Steve also is president of the Republican Main Street Partnership, which is dedicated to supporting a pragmatic, fiscally conservative “governing majority” where political debate is encouraged to promote solutions to improve the lives of all Americans.
Before deciding not to seek re-election to a 10th term in Congress, Steve had become one of Speaker John Boehner's closest colleagues in the House. In 2007, Boehner asked Steve to serve as the Dean of the Ohio Republican Delegation and Ohio representative on the Republican Steering Committee, which chooses committee chairs and members. He was appointed in 2009 to the prestigious House Appropriations Committee, which provides funding for all federal government programs with the exception of mandatory spending programs like Social Security and Medicare.
For 12 years, Steve served on the Financial Services Committee. He wrote the identity theft portion of the reauthorization of the Fair Credit Reporting Act, including the provision that now truncates the credit card number on customer receipts.
He also served on three subcommittees – Transportation, Housing and Urban Development (HUD); Interior, Environment and Related Agencies; and Legislative Branch. He served 14 years on the House Transportation and Infrastructure Committee in several leadership positions and was Vice Chair of the Transportation subcommittee during the 112th Congress. As a member of the Interior, Environment and Related Agencies Subcommittee, he played a role in the funding priorities for national parks, wildlife refuges, forests and other public lands, water resource protection, and cultural agencies, including the Smithsonian Institution and the Kennedy Center. And as a member of the subcommittee responsible for funding the legislative branch of government, he was especially interested in the effective use of legislative resources in serving constituents.
Steve was also actively involved in Great Lakes and environmental issues and served as Co-Chair of the influential Great Lakes Task Force for a decade. In 2005, he was named co-chair of the Northeast Midwest Coalition (NEMW) and its Manufacturing Task Force, which has oversight of the Great Lakes Task Forces. NEMW focuses on economic competitiveness and environmental quality in the Northeast and Midwest states. He was also co-founder of the Nursing Caucus and was a leading advocate for nursing issues in Congress.
Prior to his election to the House of Representatives, Steve served from 1989 to 1995 as the Lake County (Ohio) Prosecutor. In 1990, he was named Prosecuting Attorney of the Year in Ohio for his successful prosecution of 13 members of a murderous religious cult. He is a graduate of the University of Michigan and Cleveland Marshall College of Law.
Tonya Mallory, B.S., M.S.,
CEO, President and Co-Founder, Health Diagnostic Laboratory Inc.
Tonya Mallory is an award winning American entrepreneur whose pioneering work in the field of chronic disease management has helped propel the field of cardiology and related diseases into the forefront of diagnostic care. Tonya laid the groundwork for Health Diagnostic Laboratory, Inc. in 2008. Tonya currently serves as President & CEO. HDL, Inc. and still considers HDL, Inc. to be in a start-up phase in many ways. HDL, Inc. is best described as a disease management company with clinical laboratory services for both adult and pediatric patient sectors in the areas of cardiovascular disease (CVD), heart failure, stroke, diabetes mellitus (DM), metabolic syndrome (MS), and nonalcoholic steatohepatitis or fatty liver disease (NASH).
HDL, Inc. closed on the first round of capital in July 2009 and started servicing patients in November 2009. In a period of approximately 3 years, the company has grown from 11 employees In January 2010 to approximately 650 employees today.
The launch of HDL, Inc.’s new preventative model to chronic disease management based off a monumental shift in the way physicians test for life threatening conditions. “Few moments in medical history have held such promise and opportunity for the prevention of cardiovascular and related chronic diseases while enhancing the continuum of care,” said Tonya Mallory, President and CEO, HDL, Inc. “The medical community is no longer confined to limited lab results, and is in a position to now more accurately detect the unexpected.”
After graduating from high school, Tonya entered Virginia Commonwealth University as a premedical student. Although her undergraduate studies focused on biology, Tonya also completed her graduate degree with honors in forensic science. Tonya Mallory’s work in diagnostic laboratory science spans over twenty years. She worked for Wako Diagnostics, an in-vitro device manufacturer, for approximately seventeen years. She has extensive experience as a healthcare regulatory consultant for domestic and international companies. Tonya has worked with a prominent cohort of physicians to develop a comprehensive panel of tests to help physicians personalize treatment based on an expanded, total patient profile. As a result, HDL, Inc. provides earlier detection of residual risk factors pre-disposing patients to disease, more advanced evidence-based treatments, and fewer patients progressing to overt disease. “HDL, Inc. diligently works as a partner with both physician and patient to understand disease, and provide support to identify and reverse health risks,” said Tonya. HDL, Inc.’s advanced testing options allows physicians to understand their patients’ disease on a personal level and to support the individual achievement of health in a way that were never before possible.
Tonya continues to make groundbreaking discoveries and has firmly established herself as one of the most promising young intellects in the burgeoning field of laboratory diagnostic testing to guide reversal in chronic disease. Since the opening of HDL, Inc. in November of 2009, Tonya Mallory has won several career awards including: Governor's Award for Science Innovation; Top 25 Businesses of the Past 25 Years by Venture Forum; Muse Award by the Virginia Museum of Fine Arts; Influential Women Award by Virginia Lawyers; Companies to Watch by Venture Forum; Hometown Hero Award by Allen & Allen; All Stars Healthcare Technology Finalist; Style Weekly Executive Women in Business Award 2012, Ernst & Young’s 2012 Greater Washington Entrepreneur of the Year Award and most recently Ernst & Young’s 2012 National Emerging Company Winner.
Tonya Mallory was appointed to the Virginia Small Business Finance Authority Board by Governor McDonald and sits on the Boards of The American Heart Association, The Board of Trustees for the VCU School of Business, CJW Hospital System Board of Trustees, VA Chamber of Commerce and the MCV Foundation.
Tonya Mallory’s commitment to the patients and physicians served is melded together with a strong belief in her community and her family. The core values of HDL, Inc. thrive in a healthcare climate changing from diagnosis of illness to sustainment of wellness. Under Tonya Mallory’s leadership, HDL, Inc., is poised futuristically to form an efficient partnership in the integrated healthcare systems meeting the high standards expected by the global population of the 21st century.
President, American Clinical Laboratory Association
Since becoming President of ACLA in 2003, Alan Mertz has overseen a more than tripling of ACLA’s membership, greater visibility of ACLA in Congress and the Administration, expansion of ACLA membership services, meetings and programs, and a series of key advocacy successes.
ACLA took the lead in opposing a provision in the 2003 Medicare Modernization Act that would have added coinsurance for laboratory services in Medicare. From 2004-2008, ACLA led an advocacy campaign to stop the Medicare Laboratory Competitive Bidding Demonstration Project which resulted in, first, a federal court injunction against the project, followed by the statutory repeal of the project in June 2008. During the consideration of health care reform legislation in 2009-2010, ACLA took the lead in opposing proposals for a new federal tax on laboratory services as well as another attempt to impose laboratory coinsurance. In the same legislation, ACLA supported expanding coverage for the uninsured, a fair application of the “Productivity Adjustment,” provisions promoting prevention and wellness, extension of the so-called “TC Grandfather Clause,” and the “Date of Service” Demonstration.
In 2007, ACLA launched the “Results for Life” educational campaign aimed at promoting the value of laboratory services. In 2009, ACLA started its growing Associate Member program for non-laboratory health care companies and organizations as a means of broadening education and communication with the laboratory industry’s health partners.
Prior to taking the reins at ACLA, Mertz was Executive Vice President and Acting President of the Healthcare Leadership Council (HLC), and from 1980 to 1998 served in three senior staff positions in the House and Senate. He was selected as a John C. Stennis Congressional Fellow in 1996, taught as an adjunct professor at George Washington University from 1997-1999, and is a frequent lecturer at American University in Washington, DC. He holds a Masters Degree in American Politics from American University and a BA in Government from Monmouth College.
Managing Director, G2 Intelligence
Stephanie Murg is the Managing Director of G2 Intelligence, responsible for the live events business line as well as thought leadership roles in G2’s market research and advisory services.
Prior to joining G2, she was a research associate at JPMorganChase, Harvard Business School, and the National Bureau of Economic Research. She also has several years of laboratory experience in molecular and behavioral neuroscience research, with a focus on neurodegenerative disease.
Murg co-authored peer-reviewed publications in the Journal of Neuroscience, Human Gene Therapy, and Neurobiology of Learning and Memory, and co-wrote a chapter in the most recent edition of the textbook Neuropsychology of Memory. She received a bachelor’s degree in neurobiology from Harvard.
President, Health Care Development Services, Inc.
Barry Portugal is President of Health Care Development Services, Inc., a strategic business planning management consulting firm. Mr. Portugal has undergraduate and graduate degrees in business administration from the University of Illinois and the University of Pennsylvania, respectively. He also attended Northwestern Law School.
Prior to forming Health Care Development Services, Inc., in 1981, Mr. Portugal held several senior management positions with firms in the health care industry. During the 13 years Mr. Portugal spent on the corporate side of the industry, he served as sales manager, marketing manager, and corporate officer in charge of marketing for Technicon Instruments Corporation; Telemed Corporation, a division of Becton-Dickinson; and Damon Corporation.
Mr. Portugal consults with hospitals, large multi-specialty group practices, clinical laboratories, and pathology groups. His special area of interest is strategic planning and business development of health care providers. In this role, Mr. Portugal has designed business plans which have successfully achieved goals desired by client organizations.
Mr. Portugal is a member of the American Hospital Association Society for Hospital Planning, Clinical Laboratory Management Association, the American Association for Clinical Chemistry, the American Pathology Foundation, and the Medical Group Management Association. Additionally, Mr. Portugal has had written articles published in Clinical Laboratory Management Review, Pathologist, and the Medical Group Management Association Journal. He has been a featured speaker at meetings of the American Hospital Association, Health Care Financial Management Association, American College of Healthcare Executives, Clinical Laboratory Management Association, and the American Pathology Foundation, focusing on hospital laboratory strategic planning and business development.
President, Vachette Pathology
Mick Raich is the founder of Vachette Pathology. He is a nationally recognized consultant in the business of pathology and laboratory billing. His easy style and get-it-done personality have allowed him to become the industry leader in this field.
Mr. Raich has spent his entire 26 year career in health care. His experience includes direct patient care, hospital management, and working at a pathology billing company. For the last seven years Mr. Raich has served as the President/CEO of Vachette Pathology.
Over the years Mr. Raich has presented at every major national pathology and laboratory society conference and numerous state societies. He is frequently quoted, interviewed, and published as a specialist in this field. Mr. Raich is an ardent supporter of PathPAC and a member of MGMA.
Charles B. Root, Ph.D.,
CEO, CodeMap LLC
Dr. Charles Root is CEO of CodeMap, LLC. He has provided laboratory coding and reimbursement information to healthcare providers and manufacturers for over 22 years regarding compliance, coding and economic issues.
CodeMap’s clients include more than 50 diagnostic test manufacturers and over 1,500 health care providers (hospitals, independent laboratories and imaging centers) who rely on CodeMap publications, compliance training, and advisory services.
Publications by Dr. Root include: the CodeMap® Medicare Reimbursement Manual for Laboratory and Pathology, the CodeMap® Medicare Reimbursement Manual for Radiology and Nuclear Medicine, and the CodeMap® ICD-10-CM (Diagnosis) Reference Manual.
Dr. Root received his Ph.D. in physical chemistry and nuclear physics from the Catholic University of America, Washington, D.C., and has taken postgraduate courses in business management and economics from Harvard and Northwestern Universities. His experience includes market research, product development, and studies on the economic impact of government regulations on healthcare delivery costs.
Managing Editor, G2 Intelligence
As Managing Editor, Kimberly Scott oversees publication of G2 Intelligence’s newsletters: Laboratory Industry Report; G2 Compliance Report; National Intelligence Report; and Diagnostic Testing & Technology Report.
She has 25 years of experience covering health care issues, both on a national and local level. Since 2001, Kimberly has covered the clinical laboratory and diagnostic testing industries, with an emphasis on business strategy, operations, and compliance. Prior to that, she covered long-term care, mental health, and disability issues for business-to-business publications and wrote about federal health care for U.S. Medicine. Kimberly got her start in writing and reporting at the Daytona Beach News-Journal, where she worked first as a general assignment reporter, and later covered the medical beat.
She has a bachelor’s degree in journalism from Florida Southern College and a master’s degree in English from the University of Maryland.
Principal, Clinical Lab Business Solutions LLC
Michael Snyder is the Principal for Clinical Lab Business Solutions (CLBS), a consulting firm that works with laboratories to deliver collaborative solutions to health plans and employer groups. Mike has 30 years of experience in the management of clinical laboratories. This knowledge, combined with the work Mr. Snyder did inside of a national health plan, has given him the tools to form CLBS and, Laboratory Management Services, a management services company that provides value to the health insurance and laboratory industries. Prior to forming CLBS, he was Vice President of Laboratory Networks for UnitedHealthcare (UHC). In that capacity, he directed the national strategy for laboratory services and participated in the development of UHC’s national provider network. Additionally, Mr. Snyder served as Director of Business Development for Mount Sinai Hospital’s Center for Clinical Laboratories, where he saw outreach revenues triple in the implementation of a business plan that focused efforts on billing solutions and demonstrated the value of the medical center’s laboratory to attending faculty. Finally, Mike also served as an executive with LabCorp (1980-2000), one of the largest commercial laboratories in the US. Mike is a frequent speaker on the subject of managed care contracting and the value of managed networks for laboratory services.
Vice President, Laboratory Services, Kaleida Health
Gregory Solak, Vice President, Laboratory Services, Kaleida Health, has over 30 years of experience in laboratory and healthcare leadership. He has worked in and consulted for a number of large healthcare systems undertaking laboratory consolidations and outreach expansions. Cited as Top 50 in Health Care 2013 by Buffalo Business First, Greg is currently engaged in various and sweeping plans to further advance Kaleida Health Laboratories as the premier diagnostic resource to the physicians, patients, and payers of Western New York.
Christopher A. Tormey, M.D.,
Assistant Professor of Laboratory Medicine, Yale University School of Medicine and VA Connecticut Healthcare System
Christopher A. Tormey is Assistant Professor of Laboratory Medicine at the Yale University School of Medicine. Board-certified in clinical pathology and blood banking/transfusion medicine, he has played an important role in initiatives to control costs and improve outcomes at the Veterans Affairs Connecticut Health System in New Haven.
Dr. Tormey has several research interests within the field of transfusion medicine, ranging from large clinical studies to translational research projects. Areas of current investigation include blood bank-based immunohematology where the properties of red blood cell alloantibodies in veteran populations are examined. In addition, he is interested in studying the biochemical and immunologic effects of storage on platelet, red blood cell, and plasma components in the blood bank. He is currently developing an assay to gauge the impact of storage on the platelet granule release reaction and is also investigating the influence of donor innate immune factors on bacterial contamination of red cell and plasma products. These projects have been performed in collaboration with Dr. Gary Stack of the Department of Laboratory Medicine at Yale.
Dr. Tormey received his M.D. from New York Medical College and earned a BA in chemistry from the University of Chicago. He completed a residency in clinical pathology and laboratory medicine as well as a fellowship in transfusion medicine, both at the Yale School of Medicine.
Douglas M. VanOort,
Chairman of the Board of Directors and Chief Executive Officer, NeoGenomics Laboratories
Mr. VanOort has served as the Chairman of the Board of Directors and Chief Executive Officer of NeoGenomics since October 28, 2009. Prior to that he served as Chairman of the Board of Directors, Executive Chairman and Interim Chief Executive Officer from March 2009 to October 2009. He has been an Operating Partner with Summer Street Capital Partners since 2004 and a Founding Partner of Conundrum Capital Partners since 2000. From 1995 to 1999, he served as the Senior Vice President Operations for Quest Diagnostics, Incorporated. During this period Quest Diagnostics grew to approximately $1.5 billion in annual revenue through both organic growth and mergers and acquisitions. From 1982 to 1995, Mr. VanOort served in various positions at Corning Incorporated and ultimately held the position of Executive Vice President and CFO of Corning Life Sciences, Inc. In 1995, Corning spun off Corning Life Sciences, Inc. into two companies, Quest Diagnostics and Covance, Inc. Mr. VanOort serves as a member of the Board of Directors of several privately held companies. In addition, since 2000, Mr. VanOort is the Co-Owner of Vision Ace Hardware, LLC, a retail hardware chain. Mr. VanOort is a graduate of Bentley University.
Francisco Velàzquez, M.D., S.M.,
President and CEO, PAML LLC & PAML Ventures
Francisco R. Velàzquez is the President and Chief Executive Officer for PAML, LLC and PAML Ventures. Prior to joining PAML, he was Managing Director for the Quest Diagnostics Nichols Institute, and Vice President for Focus Diagnostics. Dr. Velàzquez trained at the Mallory Institute of Pathology in Boston and the Boston University Medical Center, and is board-certified by the American Board of Pathology. Subsequent to his training, Dr. Velàzquez obtained a Masters in Health Care Management and Policy at the Harvard School of Public Health. In addition to being a nationally known Pathologist, Dr. Velàzquez has extensive experience as a physician executive specifically in system integration, regionalization, mergers and acquisitions, and financial turnarounds in Healthcare Systems, IDNs, and large academic medical centers.
He is former Professor and Chairman for the Department of Pathology and Anatomical Sciences at the State University of New York at Buffalo, and former Professor and Vice Chairman of the Department of Pathology at the University of Texas Southwestern Medical Center. Dr. Velàzquez has also held academic and clinical appointments at Boston Medical Center, Boston University Medical Center, Wayne State School of Medicine, the Detroit Medical Center, SUNY at Buffalo, and Kaleida Health.
A former Commissioner for Laboratory Accreditation for the College of American Pathologists, Dr. Velàzquez has held elected office in the CAP House of Delegates and has been a member of several CAP committees. He is currently serving on the Health Sciences & Services Authority (HSSA) Board of Directors in Spokane, Washington.
Principal/CEO, DV & Associates, Inc.
Having been Director of Sales and Marketing and Senior Consultant for a national coding and reimbursement firm for nearly five years, Diana Voorhees developed DV & Associates, a coding and reimbursement firm that provides consulting for physicians and facilities in all specialties. Ms. Voorhees has created a network of consultants with various health care backgrounds in order to provide quality, credible, and resourceful results for all consulting services. DV & Associates has been incorporated in excess of 14 years.
Ms. Voorhees initiated her career in laboratory medicine within the Division of Hematology, Department of Medicine, at the University of Utah. She has also worked with the Division of Hematology at The Ohio State University, the Clinical Chemistry Department at Holy Cross Hospital in Salt Lake City, and the Special Hematology and Hemostasis Laboratory at the University of Utah. She spent 14 years as an Associate Clinical Professor and administrative faculty of Medical Laboratory Sciences in the College of Pharmacy at the University of Utah. During her last year and a half in academia, she was recruited as Program Director to design, implement, and direct the program in cytotechnology in the Department of Pathology.
Upon leaving the university setting, Ms. Voorhees joined Coulter Corporation and provided technical support, customer training, and education, primarily in the western United States. She was recruited by a national coding and reimbursement consulting firm, Med-Index/Medicode, where she spent nearly five years developing and marketing the consulting services for hospitals and other facilities, performing consulting engagements, providing seminars for national associations, enhancing product development, and serving on various corporate committees.
Ms. Voorhees has authored/edited several articles for professional publications including Compliance Report, a monthly column in Advance Newsmagazine, MLO, Lab Medicine, ASCLS Newsletter, G2 Compliance Report, National Intelligence Report, and the Laboratory Compliance Insider newsletters. She has provided numerous seminars, teleconferences and audio conferences for various companies and organizations. Additionally, she completed a chapter on coding and reimbursement for a well-known textbook on administration.
Ms. Voorhees consults in pathology, radiology, oncology, and other diagnostic and therapeutic specialties. Her firm consults in all physician specialties and in all outpatient settings.
Executive Editor, G2 Intelligence and Program Chair
One of the nation’s leading experts on the clinical diagnostic laboratory and pathology sectors, Dennis Weissman is President of Dennis Weissman & Associates, LLC and founder and Executive Editor of G2 Intelligence, an independent news and information company serving the health care industry.
Founded in 2004, Dennis Weissman & Associates, LLC provides public policy and strategic business intelligence and advice for the health care industry. Dennis is a well-known speaker before health care professional and industry trade groups nationwide. Prior to founding Washington G-2 Reports in 1979, he was Director of the Washington Office of the American Society for Medical Technology, and before that, worked as Special Assistant in the Office of the nation’s top health official in the U.S. Department of Health, Education, and Welfare.
He holds a bachelor’s degree in political science from the State University of New York at Buffalo and a master’s degree in higher education administration from Indiana University.
Vice President of Commercialization Strategies, Consulting, and Industry Affairs, XIFIN
Ms. Wolf is a nationally recognized expert in the field of laboratory commercialization and reimbursement, with over 20 years of experience in the diagnostic laboratory industry, specializing in Molecular Diagnostic Laboratories. She lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the U.S.
She is a former President and board member of the California Clinical Laboratory Association and is an active participant with the ACLA (American Clinical Laboratory Association) and the Personalized Medicine Coalition. Most recently Ms. Wolf held the position of Vice President of Reimbursement and Regulatory Affairs at Axial Biotech, Inc. where she was responsible for creating and implementing their successful reimbursement strategies. Prior to joining Axial Biotech, Inc., Ms. Wolf held executive positions in the area of commercialization and reimbursement at RedPath Integrated Pathology, Inc., Genomic Health, Inc., and Esoterix (now LabCorp).
Ms. Wolf has a Bachelor of Arts degree from UCLA and a Masters of HealthCare Administration.